Aurobindo Pharma share price gained marginally on February 9 despite the company received 11 observations following an inspection from United States Food and Drug Administration (USFDA).
At 09:30am, Aurobindo Pharma was quoting at Rs 1,195, up Rs 3.85, or 0.32 percent, on the BSE.
The USFDA inspected unit-III, a formulation manufacturing facility, of Eugia Pharma Specialities, a wholly owned subsidiary of the company, situated at Telangana.
The said inspection done between January 27 to February 06, 2026.
The inspection concluded with 11 observations, which are procedural in nature and will be responded to within the stipulated time, company said.
Catch all the market action on our live blog
In the previous trading session, the stock closed at ₹1,191.15, gaining ₹8.65, or 0.73 percent. The share has touched a 52-week high of ₹1,278 on April 24, 2025, and a 52-week low of ₹994.35 on April 7, 2025.
At current levels, the stock is trading about 6.8 percent below its 52-week high and nearly 19.79 percent above its 52-week low. The company’s market capitalisation stands at ₹69,182.19 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
